• Home
  • Resources
  • Nephrology Articles
  • Diabetic Kidney Disease
  • SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

CREDENCE Trial Investigators
Google Plus
LinkedIn
ukidneyisup